联合应用低分子肝素与氯吡格雷治疗缺血性脑血管病的临床效果观察

The low molecular weight heparin and clopidogrel clinical effect of treatment of ischemic cerebrovascular disease

目的观察联合应用低分子肝素与氯吡格雷治疗缺血性脑血管疾病的临床效果。方法将2011年9月~2013年7月我院收治的78例缺血性脑血管疾病患者作为研究对象,将其随机分为研究组(40例)与对照组(38例)。为对照组患者应用阿司匹林进行治疗,为研究组患者联合应用低分子肝素与氯吡格雷进行治疗,然后对比分析其临床疗效。结果与对照组患者相比,研究组患者在进行治疗后其PLT、PT及APTT改善的幅度较大,差异显著(P<0.05),有统计学意义。研究组患者不良反应的发生率低于对照组患者,差异显著(P<0.05),有统计学意义。结论联合应用低分子肝素与氯吡格雷治疗缺血性脑血管病可取得理想的效果,而且用药的安全性较高,此法值得在临床上推广应用。

Objective:To observe the low molecular weight heparin and clopidogrel in patients with the clinical effects of ischemic cerebrovascular disease were analyzed observation. Methods The clinical data of 78 cases of patients with ischemic cerebrovascular disease. Results of the study group of patients PLT, PT, APTT adverse reaction rates and other indicators and other indicators are better than the control group (p <0.05). Conclusions Treatment of patients with ischemic cerebrovascular disease take low molecular weight heparin and clopidogrel therapy, can significantly enhance the therapeutic effect and reduce the rate of adverse reactions.